Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canakinumab biosimilar - GENERIUM Pharmaceuticals

Next Previous
X
Search
Drug Profile

Canakinumab biosimilar - GENERIUM Pharmaceuticals

Alternative Names: GNR 086

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GENERIUM Pharmaceuticals
  • Class Anti-inflammatories; Antianaemics; Antigouts; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Heart failure therapies; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Adult-onset Still's disease
  • Phase II/III Juvenile rheumatoid arthritis

Most Recent Events

  • 21 Mar 2024 Phase-II/III clinical trials in Juvenile rheumatoid arthritis in Russia (Parenteral), prior to March 2024 (Generium Pharmaceuticals pipeline, March 2024)
  • 21 Mar 2024 Preclinical trials in Juvenile rheumatoid arthritis in Russia (Parenteral), prior to March 2024 (Generium Pharmaceuticals pipeline, March 2024)
  • 26 Mar 2023 AO GENERIUM completes a phase I trial (In volunteers) in Russia(SC, Injection) (NCT06481189)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top